



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 039 369
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 80102385.4

(51) Int. Cl.: C 07 J 5/00, A 61 K 9/72
// A 61 K 31/57

(22) Date of filing: 02.05.80

(43) Date of publication of application: 11.11.81
Bulletin 81/45

(71) Applicant: SCHERING CORPORATION, 2000 Galloping
Hill Road, Kenilworth, New Jersey 07033 (US)

(72) Inventor: Finckenor, Lawrence Edward, 15 Barbara Way,
Wayne New Jersey 07470 (US)

(64) Designated Contracting States: AT BE CH DE FR GB IT
LI NL SE

(74) Representative: Antony, Fritz, Dr. et al, P.O.
Box 601 Winkelriedstrasse 35, CH-6002 Lucerne (CH)

(54) Beclomethasone ester solvates, process for their preparation, and preparation of a formulation.

(57) The present invention relates to novel solvates of beclomethasone dipropionate with alkanes, especially n-alkanes, having from 5 to 8 carbon atoms, and to their preparation, e.g. by contacting beclomethasone dipropionate with the alkane. The novel solvates can be used in inhalation devices and in the preparation of beclomethasone dipropionate-trichlorofluoromethane solvate.

EP 0 039 369 A1


BEST AVAILABLE COPY

TITLE MODIFIED
see front page

"BECLOMETHASONE ESTER SOLVATES"

This invention relates to novel solvates of a beclomethasone ester, namely beclomethasone dipropionate, to processes for their preparation, and to their use in the
5 preparation of aerosols.

Beclomethasone dipropionate is 9 α -chloro-16 β -methyl-1,4-pregnadiene-11 β ,17 α ,21-triol-3,20-dione 17 α ,21-dipropionate and has the following structural formula:



10 It is a useful drug for the treatment of chronic allergic asthma (Brit. Med. J., 1, 585-590 (1972)) and is typically administered in an aerosol unit containing a microcrystalline suspension of beclomethasone dipropionate in a

propellant, usually trichlorofluoromethane. The drug must be micronized prior to use in an aerosol formulation in order to obtain particles of medicinally effective size. However, when unsolvated drug is introduced into the aerosol formulation, the micronised drug particles solvate and undergo crystal growth, which reduces the amount of drug of suitable particle size available in the spray and also causes the aerosol spray valves to clog. To overcome this problem of crystal growth, it has been found useful to prepare a solvate of the drug with the trichlorofluoromethane propellant prior to micronization of the drug (British Patent Specification No. 1,429,184). The drug solvate is then micronized and mixed with the remaining aerosol propellants. Although the beclomethasone dipropionate-trichlorofluoromethane solvate thus enables one to prepare a suitable aerosol form, it presents other manufacturing difficulties in that the solvate when stored as bulk is not stable with respect to trichlorofluoromethane. Trichlorofluoromethane is released when the solvate is stored at room temperature or above, and thus the solvate must be used rather promptly or be stored under refrigeration. Storage under refrigeration is both expensive and inconvenient, particularly when the drug solvate is to be shipped in bulk. Moreover, a substantial portion (up to one third) of the trichlorofluoromethane is lost from the trichlorofluoromethane solvate during the micronization. The loss of the trichlorofluoromethane from the drug

solvate results in a loss of micronized drug in the aerosol formulation since (as mentioned above) any unsolvated drug will tend to undergo crystal growth and thus not be medically available in the aerosol spray. The lost trichloro-
5. fluoromethane is also a potential environmental hazard.

The present invention is based upon the surprising discovery that beclomethasone dipropionate forms solvates with alkanes which are substantially stable with respect to alkane when stored as bulk.

10 The present invention therefore provides solvates of beclomethasone dipropionate with alkanes having from 5 to 8 carbon atoms. For the purposes of this invention we define the term "solvate" as a crystalline material in which the steroid beclomethasone dipropionate and the
15 alkane are associated. No particular method of association is implied, but it is possible that the alkane occupies "holes" in the crystal lattice of the steroid. The solvate normally contains from 4 to 8% by weight of alkane, the amount depending upon the particular method of preparation
20 as well as upon the alkane itself. The alkane is preferably an n-alkane, i.e. n-pentane, n-heptane or n-octane, or especially n-hexane.

The accompanying drawing shows the infrared absorption spectrum of a mull of beclomethasone dipropionate-n-hexane solvate in mineral oil (sold under the Trade Mark "Nujol"). In the drawing the vertical scale indicates the transmittance (shown by " $T (\%)$ "), and the horizontal scale indicates the frequency in cm^{-1} (shown by " $\nu (\text{cm}^{-1})$ ") and the wavelength in microns (shown by " $\lambda (\mu)$ "). This sample of solvate contained 4-5% of n-hexane by weight. Beclomethasone dipropionate-n-hexane solvate normally contains 4 to 6% by weight of n-hexane, in particular about 4.6% or 5.3% by weight of n-hexane.

The infrared spectra of beclomethasone dipropionate-n-pentane solvate and of beclomethasone dipropionate-n-heptane solvate are very similar to the spectrum shown in the accompanying drawing, in that all these spectra have absorption bands in almost identical positions. The relative intensities of some absorption bands may vary, depending upon the n-alkane in the solvate and how much of it is present in the solvate. A particular solvate may also show a few absorption bands not characteristic of other solvates.

The beclomethasone dipropionate-alkane solvates are stable with respect to the alkane at moderate temperatures. In particular, beclomethasone dipropionate-n-hexane solvate is

stable with respect to n-hexane at temperatures up to about 100°C.; n-hexane is first lost at about 105°C. (as shown by differential thermal analysis). The n-hexane solvate can however be broken at 80°C. under vacuum.

5 The solvates according to the invention can be prepared by intimately contacting beclomethasone dipropionate with an alkane having from 5 to 8 carbon atoms. Although it may be convenient under particular circumstances to contact micro-
nised beclomethasone dipropionate with the alkane, it is
10 generally preferable to allow the beclomethasone dipropionate to crystallise out of an organic solvent medium comprising the alkane. Although the organic solvent medium may be pure alkane (e.g. if the beclomethasone dipropionate is extracted out of a Soxhlet), it preferably comprises the al-
15 kane and an organic solvent that is completely miscible therewith, e.g. chloroform, tetrahydrofuran, dioxan, di-isopropyl ether, diethyl ether, ethyl acetate, cyclohexane, acetonitrile, isopropanol, or especially methylene chloride or acetone. The alkane is preferably an n-alkane, i.e.
20 n-pentane, n-heptane or n-octane or especially n-hexane. The solvate is conveniently prepared by dissolving the beclomethasone dipropionate in a suitable organic solvent (such as one mentioned above) and then adding the alkane; preferably the original solvent is then at least partly removed by
25 distillation, while further alkane is added to maintain total

solvent volume. After cooling, the precipitated solvate is filtered off and dried.

The alkane solvates of this invention and in particular the n-hexane solvate of beclomethasone dipropionate are simpler, to prepare than the known trichlorofluoromethane solvate, in that they can be prepared without using the large volumes of solvating medium that the trichlorofluoromethane solvate needs.

The novel beclomethasone dipropionate-alkane solvates are suitable for use in the preparation of beclomethasone dipropionate-trichlorofluoromethane solvate especially of an appropriate particle size (e.g. 1 to 10 μ) for use as active ingredient of an aerosol formulation. The invention therefore provides a process for the preparation of beclomethasone dipropionate-trichlorofluoromethane solvate which comprises bringing a solvate of beclomethasone dipropionate with an alkane having 5 to 8 carbon atoms into contact with trichlorofluoromethane. Preferably the alkane solvate is micronised, so that the resulting trichlorofluoromethane solvate is also micronised. The method of preparation of beclomethasone dipropionate-trichlorofluoromethane solvate according to the present invention furthermore has the advantage of not requiring such large volumes of trichlorofluoromethane as are required by the known method. For

example, when the beclomethasone dipropionate-n-hexane solvate is contacted with a relatively small volume of trichlorofluoromethane, e.g. 15 litres per kg, of solvated steroid, the n-hexane of solvation is exchanged for trichlorofluoromethane so that beclomethasone dipropionate-trichlorofluoromethane solvate is formed. (Preparation of the trichlorofluoromethane solvate by the method of British Patent Specification No. 1,429,184, Example 2, would require about 140 litres of trichlorofluoromethane per kg. of steroid.)

10 This process is preferably carried out on micronised beclomethasone dipropionate-n-hexane solvate so that micronised beclomethasone dipropionate-trichlorofluoromethane solvate is isolated. Alternatively and preferably, micronized beclomethasone dipropionate-alkane solvate (especially
15 the n-hexane solvate) may be placed directly in the aerosol canister with the trichlorofluoromethane propellant to afford in situ an aerosol formulation in which the beclomethasone dipropionate does not exhibit significant crystal growth and exists in a particle size suitable for local
20 ~~absorption.~~

Since the beclomethasone dipropionate-trichlorofluoromethane solvate prepared by this method retains substantially the particle size of the micronized beclomethasone dipropionate-alkane solvate, it may be used
5 directly without further micronization in an aerosol formulation, so that loss of trichlorofluoromethane and consequent crystal growth on resolution can be avoided.

The amount of alkane (e.g. n-hexane) present in the solvate of this invention is considered biologically in-
10 significant and thus the alkane solvate may be used directly in a formulation without toxic effects.

The aerosol propellants and valves suitable for use in this feature of the invention are standard and well known in the art. A particularly suitable inhaler
15 is the inhaler presently marketed under the Trade Mark Vanceril.

The following examples illustrate but do not limit the present invention:

EXAMPLE 1Beclomethasone Dipropionate-n-Hexane Solvate

Dissolve 300 g. of beclomethasone dipropionate in 2
liters of methylene chloride at reflux. Treat with 15 g.
5 activated charcoal for 15 minutes at reflux and filter
while hot. Concentrate the filtered solution to a vo-
lume of 900 ml. and while maintaining reflux add slowly
900 ml. of n-hexane. Cool to 0-10°C. Filter off the
resulting precipitate and wash it with n-hexane. Dry
10 the precipitate in air below 50°C. to constant weight
to afford beclomethasone dipropionate-n-hexane solvate
having an $[\alpha]_D^{25} = +85.5^\circ \pm 2^\circ$ in dioxan and an $\epsilon_{1\%}$
(extinction coefficient) in 1% solution = 275 ± 10 at
239 m μ . Analysis by gas chromatography shows an n-
15 hexane content of 4.6%. The beclomethasone dipropionate
content (determined by ultraviolet assay) is 94.5%.

EXAMPLE 2Beclomethasone Dipropionate-n-Hexane Solvate

Dissolve 100 g. of beclomethasone dipropionate in 1.5
20 liters of acetone at reflux. Treat with 5 g. of acti-
vated charcoal for 15 minutes and filter while hot. Con-
centrate the filtered solution to 0.5 liter. While
maintaining reflux, slowly add 0.5 liter of n-hexane.

Cool to 0-10°C. Filter off the resulting precipitate and wash it with cold n-hexane. Dry the precipitate in air at 50°C. to constant weight to yield beclomethasone dipropionate-n-hexane solvate. The beclomethasone dipropionate content (determined by ultraviolet assay) is 94.6%.

EXAMPLE 3

Beclomethasone Dipropionate-n-Hexane Solvate

Under reflux, dissolve 20 g. of beclomethasone dipropionate in 100 ml. of methylene chloride. If necessary, treat with activated charcoal and filter. Slowly add 400 ml. of n-hexane while distilling at a rate that maintains a batch volume of 100 ml. Reflux the batch at a volume of 100 ml. (b.p. 68°C.) for half an hour. Cool slowly to 0-5°C.; filter, wash the precipitate with n-hexane, and dry it at 60°C. to constant weight; yield 21 g. n-Hexane by gas chromatography assay (two samples): 5.29%; 5.07%.

EXAMPLE 4

Beclomethasone Dipropionate-n-Hexane Solvate

Under reflux, dissolve 50 g. of beclomethasone dipropionate in 250 ml. of acetone. If necessary, treat with activated charcoal and filter. Distil at a slow rate adding

n-hexane just fast enough to maintain the original batch volume. Continue the distillation until 1 liter of n-hexane has been added and the batch has a volume of 250 ml. and a boiling point of 68°C. Reflux the batch for half an hour and cool it slowly to 0-5°C. Filter off the precipitate, wash it with n-hexane, and dry it in the air at 60°C. to constant weight; yield 52.8 g.

n-Hexane by gas chromatography assay (three samples):
5.34%; 5.33%; 5.78%.

EXAMPLE 5

Beclomethasone Dipropionate-n-Pentane Solvate

Under reflux, dissolve 2 g. of beclomethasone dipropionate in 15 ml. of methylene chloride. Add 10 ml. of n-pentane and concentrate to 15 ml. Continue the addition/concentration sequence until 150 ml. of pentane has been added and the batch has a volume of 15 ml. and a boiling point of 36°C. Cool slowly to 0-5°C. Filter off the precipitate, wash it with n-pentane, and dry it at 60°C. in air to constant weight; yield 1.99 g., $[\alpha]_D^{26}$ (dioxan) +88.9°,

$\epsilon_{1\%}^{1\text{cm}}$ in MeOH = 285 at 238 m μ . n-Pentane by gas chroma-

tography assay: 4.39%.

EXAMPLE 6Beclomethasone Dipropionate-n-Heptane Solvate

Under reflux dissolve 2 g. of beclomethasone dipropionate
5 in 25 ml. of methylene chloride. Add 7 ml. of n-heptane
and bring to reflux under partial vacuum. Slowly add
140 ml. of n-heptane while distilling under reduced pres-
sure so as to maintain a volume of 25 ml. Stir for half
an hour at room temperature. Cool to 0-5°C., filter
10 off the precipitate, wash it with n-heptane and dry it in
air at 60°C. to constant weight; yield 2.1 g., $[\alpha]_D^{26}$
(dioxan) = +85.5°, $\epsilon_{1\%}^{1\text{cm}}$ in MeOH = 277 at 238 m μ .
n-Heptane by gas chromatography assay: 7.32%.

FORMULATION EXAMPLE

Beclomethasone Dipropionate Inhaler

<u>Formula</u>	<u>mg/container (200 doses)</u>
Beclomethasone Dipropionate*(micronized)	10.0
5 Oleic Acid	1.0
Trichlorofluoromethane	4,739.0
Dichlorodifluoromethane	<u>12,250.0</u>
to make	17,000.0

10 *Charged as beclomethasone dipropionate-n-hexane solvate equivalent to 10 mg. of beclomethasone dipropionate.

Procedure

Add oleic acid to previously cooled trichlorofluoromethane and mix with a high-shear mixer. While mixing, add the required amount of beclomethasone dipropionate-n-hexane solvate and continue mixing until homogeneous. If necessary, adjust the suspension to the required weight with trichlorofluoromethane. Meter the required amount of suspension into each can. Crimp the valves onto the cans. Pressure-fill through the valves the required amount of dichlorodifluoromethane.

C L A I M S

1. Solvates of beclomethasone dipropionate with alkanes having from 5 to 8 carbon atoms, especially with n-alkanes such as n-pentane and n-heptane and in particular with n-hexane, and preferably containing from 4 to 8% by weight of alkane.

2. Beclomethasone dipropionate-n-hexane solvate containing from 4 to 6%, especially about 4.6% or about 5.3%, by weight of n-hexane, and in particular having an infrared spectrum on a suspension thereof in mineral oil substantially as shown in the accompanying drawing.

3. A process for the preparation of a solvate as claimed in claim 1 which comprises intimately contacting beclomethasone dipropionate with an alkane having from 5 to 8 carbon atoms, especially by allowing beclomethasone dipropionate to crystallise out of an organic solvent medium comprising an alkane having from 5 to 8 carbon atoms.

4. A process as claimed in claim 3 wherein the organic solvent medium comprises the alkane and an organic solvent that is completely miscible with the alkane, such as chloroform, tetrahydrofuran, dioxan, di-isopropyl ether, diethyl ether, ethyl acetate, cyclohexane, acetonitrile or isopropanol, or especially methylene chloride or acetone.

5. A process as claimed in claim 3 or claim 4 wherein the alkane is n-pentane or n-heptane or especially n-hexane.


6. A process for the preparation of beclomethasone dipropionate-trichlorofluoromethane solvate, which comprises bringing a solvate as claimed in claim 1 of beclomethasone dipropionate with an alkane having 5 to 8 carbon atoms into contact with trichlorofluoromethane.

7. A process for the preparation of micronised beclomethasone dipropionate-trichlorofluoromethane solvate which comprises bringing a micronised solvate of beclomethasone dipropionate with an alkane having 5 to 8 carbon atoms, especially n-hexane, into contact with trichlorofluoromethane.

8. A process as claimed in claim 7 wherein the beclomethasone dipropionate-trichlorofluoromethane solvate is formed in situ in an aerosol formulation.
9. A method of preparing an aerosol formulation of beclomethasone dipropionate which comprises the step of placing a micronised solvate claimed in claim 1, especially beclomethasone dipropionate-n-hexane solvate, in an aerosol propellant, especially an aerosol propellant comprising trichlorofluoromethane.
10. Each and every novel compound, composition, process and method herein disclosed.

0039369

1/1





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

0039369

EP 80 10 2325

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. I)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D	<p>GB - A - 1 429 184 (ALLEN AND HANBURY'S)</p> <p>* Claims 1,4,25,26 *</p> <p>---</p> <p>CHEMICAL ABSTRACTS, vol. 90, no. 24, 11th June 1979, column 2, page 367, no. 192558r Columbus, Ohio, U.S.A.</p> <p>& ES - A - 465 924 (CALZADA Y CIA. S.R.C.) 01-01-1979</p> <p>* Abstract *</p> <p>---</p> <p>FR - A - 2 361 900 (SYNTEX INC.)</p> <p>* Claims 1,3,6 *</p>	<p>1,9</p> <p>1,9</p> <p>3,9</p>	<p>C 07 J 5/00 A 61 K 9/72// A 61 K 31/57</p> <p>TECHNICAL FIELDS SEARCHED (Int. Cl. I)</p> <p>C 07 J 5/00 A 61 K 9/72</p>
INCOMPLETE SEARCH			CATEGORY OF CITED DOCUMENTS
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-9</p> <p>Claims searched incompletely:</p> <p>Claims not searched: 10 Method for treatment of the human or animal body by surgery or therapy (See article 52(4) of the European Patent Convention).</p> <p>Reason for the limitation of the search:</p>			<p>X: particularly relevant</p> <p>A: technological background</p> <p>O: non-written disclosure</p> <p>P: intermediate document</p> <p>T: theory or principle underlying the invention</p> <p>E: conflicting application</p> <p>D: document cited in the application</p> <p>L: citation for other reasons</p>
<p>Place of search: The Hague</p> <p>Date of completion of the search: 26-11-1980</p> <p>Examiner: HENRY</p>			<p>3: member of the same patent family, corresponding document</p>

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.